The original growth hormone-releasing peptide — simpler and gentler than newer secretagogue combinations.
Sermorelin is a synthetic analog of the first 29 amino acids of growth hormone-releasing hormone (GHRH). It was previously FDA-approved as Geref before being discontinued from the branded market for commercial, not safety, reasons, and is now available through compounding pharmacies. Its short half-life and single-receptor mechanism make it a gentler, more self-limiting starting point than combination protocols like CJC-1295/Ipamorelin.
Sermorelin acts on a single receptor with a short half-life, producing a milder, more self-limited pulse than combination protocols — a reasonable place to start before considering CJC-1295/Ipamorelin.
Because it works within the body's own feedback loop, rising GH naturally triggers somatostatin release, which caps the pulse — a built-in safety margin that exogenous HGH does not have.
Sermorelin's parent molecule was studied and used clinically for decades, including as an FDA-approved diagnostic and pediatric growth hormone deficiency product before the branded product was discontinued.
Growth hormone release is tied to slow-wave sleep, and nightly dosing works with that natural rhythm rather than against it.
One peptide, one nightly injection — a more straightforward regimen for patients who want to start conservatively.
Patients who tolerate sermorelin well and want a larger effect can discuss transitioning to CJC-1295/Ipamorelin with their physician.
Sermorelin reproduces the biologically active fragment of natural growth hormone-releasing hormone. Unlike CJC-1295, it is not chemically extended for a longer half-life, and unlike Ipamorelin, it does not touch the ghrelin receptor at all — it works through exactly one pathway.
Sermorelin binds the GHRH receptor on pituitary somatotroph cells, the same receptor natural GHRH uses.
This triggers release of growth hormone in a pulse, timed with your nightly dose.
As GH rises, the body releases somatostatin, which suppresses further GHRH signaling — a natural ceiling that limits how large any single pulse can get.
Hepatic IGF-1 rises modestly over time, which is the lab marker your physician tracks at follow-up.
Sermorelin's parent compound was FDA-approved (as Geref) for diagnostic testing and pediatric growth hormone deficiency, then discontinued from the branded market in the 2000s for commercial reasons. It is now compounded by licensed U.S. pharmacies for off-label use in adults.
CJC-1295 is chemically modified to extend its half-life, and Ipamorelin adds a second, ghrelin-receptor pathway on top of it. Sermorelin skips both modifications, which generally means a smaller effect size but also a cleaner side-effect profile — useful for patients who found combination therapy too strong or who want the most conservative entry point.
The physiology of GHRH and pulsatile GH secretion is extensively characterized, including decades of use of sermorelin's parent molecule in diagnostic and pediatric settings. Modern outcome trials specifically studying sermorelin for body composition or healthspan in healthy adults are limited, and it is prescribed off-label for that use.
As with any GH secretagogue, we check IGF-1, fasting glucose and A1c before starting and again at follow-up, since growth hormone signaling affects insulin sensitivity.
Review describing sermorelin's mechanism, safety profile, and rationale as a growth hormone secretagogue for adult-onset GH decline.
Clinical Interventions in Aging
Pharmacological review of sermorelin's receptor selectivity, half-life, and clinical use in growth hormone deficiency.
Drugs
Comprehensive review of growth hormone-releasing hormone physiology and the age-related decline in pulsatile GH secretion that underlies secretagogue therapy.
Endocrine Reviews
Illustrative only. Your physician sets and adjusts your schedule based on tolerance, labs and rate of progress — escalation is never automatic.
| Phase | Dose | Clinical note |
|---|---|---|
| Weeks 1–4 | 200–300 mcg nightly | Assess sleep quality and injection-site tolerance. |
| Weeks 5–12 | 300–500 mcg nightly | Escalate only if tolerated and progress is tracking. |
| Reassess | — | IGF-1, fasting glucose and A1c reviewed before continuing. |
| Optional next step | — | Well-tolerated patients wanting more effect may discuss CJC-1295/Ipamorelin with their physician. |
Most side effects are dose-dependent and resolve with slower titration. Your care team is reachable by message, and holding a dose is always an option.
| Therapy | Mechanism | Avg. weight change | Frequency |
|---|---|---|---|
| Sermorelin | GHRH analog only | — | Nightly |
| CJC-1295 / Ipamorelin | GHRH analog + ghrelin-receptor agonist | — | Nightly |
| Exogenous HGH | Direct hormone replacement | — | Daily |
No. HGH replaces the hormone directly and suppresses your own production. Sermorelin prompts your pituitary to release its own growth hormone in a natural, self-limited pulse.
Sermorelin uses one receptor and a short half-life, producing a smaller but cleaner effect. CJC-1295/Ipamorelin combines an extended-release GHRH analog with a ghrelin-receptor agonist for a larger pulse. Many patients start with sermorelin and move up if they want more.
Its parent molecule was FDA-approved as Geref and later discontinued from the branded market for commercial reasons. What we prescribe is compounded by a licensed U.S. pharmacy for off-label use, and your physician will review that with you.
Yes. It's a common progression for patients who tolerate sermorelin well and want a larger effect on body composition or recovery. Your physician manages the transition.
The clinical gold standard for appetite regulation.
View protocolDual incretin action for the deepest documented weight reduction.
View protocolA gastric peptide studied for systemic tissue repair.
View protocolA synthetic fragment of Thymosin Beta-4 studied for soft-tissue recovery.
View protocolA paired secretagogue protocol that supports your own growth hormone rhythm.
View protocolA mitochondrial cofactor protocol for energy, focus and cellular repair.
View protocolThe same GLP-1 signal, taken as a daily oral dose instead of a weekly injection.
View protocolA mitochondrial-derived peptide studied for metabolic flexibility and exercise-like signaling.
View protocolAn on-demand therapy that works on desire in the brain, not blood flow in the body.
View protocolIntranasal peptides studied for focus, stress resilience and neurotrophic support.
View protocolA two-minute intake, reviewed by a licensed physician. No obligation, no membership fee.